Qulipta, also known by its generic name atogepant [1], is a medication used for the preventive treatment of migraine [2].
What is Qulipta's generic name?
The generic name for Qulipta is atogepant [1].
How does Qulipta work?
Qulipta is a calcitonin gene-related peptide (CGRP) receptor antagonist. By blocking the action of CGRP, a molecule involved in migraine pain, Qulipta helps prevent migraines [2].
When did Qulipta receive FDA approval?
Qulipta received FDA approval in September 2021 [2].
What is Qulipta used for?
Qulipta is prescribed for the preventive treatment of episodic migraine in adults [2].
Who manufactures Qulipta?
AbbVie manufactures Qulipta [2].
Does Qulipta have patent protection?
Information regarding Qulipta's patent status can be found on DrugPatentWatch.com [3].
What are the potential side effects of Qulipta?
Common side effects of Qulipta include upper respiratory tract infections, nausea, and fatigue [2].
How does Qulipta compare to other migraine preventives?
As a CGRP receptor antagonist taken orally, Qulipta offers an alternative to other migraine preventive medications that may include different mechanisms of action or administration routes [2].
Sources:
[1] https://www.drugpatentwatch.com/search?query=atogepant
[2] https://www.qulipta.com/
[3] https://www.drugpatentwatch.com/